Los Angeles Capital Management
RAPP

Los Angeles Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Los Angeles Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,690
Closed -$180K – 2638
2025
Q4 		$180K Buy
+6,690
New +$185K ﹤0.01% 1270

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Los Angeles Capital Management's RAPP Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 6,690 shares — an estimated $180K sold.

Los Angeles Capital Management first reported a position in RAPP in Q4 2025 and held it in 1 quarter. The position peaked at $180K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 6,690 Rapport Therapeutics shares in Q1 2026, an estimated $180K.
  • Los Angeles Capital Management first reported a position in Rapport Therapeutics in Q4 2025 and held it in 1 quarter.
  • Los Angeles Capital Management's Rapport Therapeutics position peaked at $180K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.